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Abstract
Background: The aims of this study were: (1) to compare the discriminative ability of a disease-specific instrument,
the St. George’s Respiratory Questionnaire (SGRQ) to generic instruments (i.e., EQ-5D and SF-36); and (2), to
evaluate the strength of associations among clinical and health-related quality of life (HRQL) measures in chronic
obstructive pulmonary disease (COPD).
Methods: We analyzed data collected from 120 COPD patients in a Veterans Affairs hospital. Patients self-
completed two generic HRQL measures (EQ-5D and SF-36) and the disease-specific SGRQ. The ability of the
summary scores of these HRQL measures to discriminate COPD disease severity based on Global Obstructive Lung
Disease (GOLD) stage was assessed using relative efficiency ratios (REs). Strength of correlation was used to further
evaluate associations between clinical and HRQL measures.
Results: Mean total scores for PCS-36, EQ-VAS and SGRQ were significantly lower for the more severe stages of
COPD (p < 0.05). Using SGRQ total score as reference, the summary scores of the generic measures (PCS-36,
MCS-36, EQ index, and EQ-VAS) all had REs of <1. SGRQ exhibited a stronger correlation with clinical measures
than the generic summary scores. For instance, SGRQ was moderately correlated with FEV1 (r = 0.43), while generic
summary scores had trivial levels of correlation with FEV1 (r < 0.2).
Conclusions: The SGRQ demonstrated greater ability to discriminate among different levels of severity stages of
COPD than generic measures of health, suggestive that SGRQ may provide COPD studies with greater statistical
power than EQ-5D and SF-36 summary scores to capture meaningful differences in clinical severity.
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Background
Chronic obstructive pulmonary disease (COPD) is a
leading cause of death worldwide and is associated with
a high burden of illness [1], particularly in terms of
health-related quality of life (HRQL). COPD is charac-
terized by airflow obstruction that is not fully reversible
and symptoms such as dyspnea, sputum production, and
chronic cough [2]. Airflow limitation is usually progres-
sive; thus daily activities can become very difficult as the
condition gradually worsens. Consequently, the burden
of COPD on HRQL disease tends to increase with
COPD severity [3-6].
HRQL is inherently subjective, involving patient self-
assessment of multiple dimensions of health that often
are not strongly correlated with clinical indicators of
COPD [7,8]. Measures of self-reported HRQL and pul-
monary function assess different aspects of the disease
and therefore provide complementary information
[9,10]. Both generic and disease-specific HRQL instru-
ments are used in COPD. St. George’s Respiratory
Questionnaire (SGRQ) is a disease-specific measure
used in both COPD and asthma research [11]. EQ-5D
[12] and the SF-36 [13] are generic measures of health
often used in studies of COPD [3,5,10,14,15].
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any medium, provided the original work is properly cited.The severity of disease in a study population may affect
the choice of instruments to measure health status. For
instance, EQ-5D demonstrated fewer floor effects among
patients with more severe asthma while SF-6D, a utility-
based measure derived from items on the SF-36, demon-
strated fewer ceiling effects and thus would be a more
preferable measure to assess HRQL in patients with mild
asthma who have good disease control [16]. A meta-
analysis that examined EQ-5D index-based scores by
COPD severity found that while mean scores decreased
with the severity of GOLD stages, there was little discrimi-
nation of scores for moderate to severe stages of disease
[15]. Such studies suggest that the performance of a
HRQL measure may depend on the severity of COPD in a
patient population. We were interested in further investi-
gating the strengths and limitations of disease-specific and
generic HRQL measures, particularly EQ-5D, SF-36 and
SGRD, to better inform the selection of PRO measures in
clinically heterogeneous COPD patient populations. Thus,
aims of this study were: (1) to compare the discriminative
ability of a disease-specific HRQL instrument (i.e., SGRQ)
versus a generic instrument (i.e., EQ-5D); and (2), to eval-
uate the strength of associations among various clinical
and HRQL measurements in COPD.
Methods
Subjects
We conducted a secondary data analysis of de-identified
patient data from a study conducted in a Veterans Admin-
istration (VA) hospital. A previous publication described
how the original data was obtained [17]. First, investigators
identified patients with any inpatient or outpatient diagno-
sis of COPD in the previous 12 months and received VA
care for at least 12 months prior to the study. Next, eligi-
ble patients were contacted by mail and received a follow-
up phone call inviting them to participate in the study. If
they consented, participants came to a pulmonary function
laboratory where they completed pulmonary function
testing, a 6-minute walk test (6MWT), and several self-
reported measures, including the Borg dyspnea scale,
SGRQ, SF-36, and EQ-5D. Respondents also completed a
brief demographic questionnaire that asked about smoking
history, including number of years that they smoked and
average number of packs smoked per day. Number of
pack-years was calculated based on number of years
smoked (smoke-year) multiplied by average number of
packs of cigarettes smoked per day (packs/day). As the
present study was conducted using only de-identified data,
it was granted exempt status by the UIC Office for the
Protection of Research Subjects.
Measures
We used forced expiratory volume in 1 second (FEV1)
and forced expiratory vital capacity (FVC) to assess lung
function. According to The Global Initiative for chronic
Lung Disease (GOLD) guidelines [2], once airway
obstruction is established based on a FEV1/FVC ratio of
<0.70, COPD are categorized into 4 stages of disease:
mild (FEV1 ≧ 80%), moderate (FEV1 ≧ 50-79%), severe
(FEV1 ≧ 30-49%), and very severe (FEV1 < 30%) [18].
FEV1 was expressed as a percentage of predicted nor-
mal values based on age, gender and height [19]. 6MWT
is a widely used assessment of functional status in
patients with COPD. It measures the distance (in meters)
t h a tap a t i e n tc a nw a l ko nt h e i ro w np a c ei ns i xm i n u t e s .
Dyspnea was measured on the Borg dyspnea scale [20].
Borg scores range from 0 (no breathlessness) to 10
(maximum breathlessness).
SGRQ is self-administered and includes 50 items in
three components: symptoms, activity, and impact on
daily life [21]. The SGRQ scores range from 0 to 100,
with 0 indicating no impairment in the quality of life.
Higher scores on the SGRQ represent worse HRQL.
MID of four points was proposed for the SGRQ total
score.
The veterans SF-36 is a slightly modified version of
the SF-36 [13,22] that consists of 8 domains: general
health, physical functioning, role function, role emo-
tional, bodily pain, vitality, social functioning, and men-
tal health. In addition, two summary scores, a physical
component summary (PCS) and mental component
summary (MCS) score can be calculated. The main
modification made to the veterans SF-36 was to expand
the number of response options from 2 to 5 for the role
functioning scales due to physical health problems or
emotional problems, which improved the properties of
scales and the summary scores [23].
EQ-5D is a generic, preference-based utility instru-
ment that includes a descriptor health classifier and a
visual analog scale (VAS) [12]. The self-classifier has five
dimensions including mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. An index-based
utility score was calculated using algorithms for societal
preference weights from the United Kingdom [24] and
from the United States [25]. The VAS score is a rating
of health today by the respondent where 0 represents
worst imaginable health state and 100 represents best
imaginable health.
Statistical Analysis
Chi-square tests were used to test whether there were dif-
ferences in patient characteristics for nominal variables
across stages of COPD. Differences in means for continu-
ous variables were examined using analysis of variance
(ANOVA) and the non-parametric equivalent (Kruskal-
Wallis) tests across the four stages of severity. Relative
efficiency (RE) ratios were calculated by taking the ratio of
the ANOVA-based test statistics, e.g. F-statistics, associated
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SGRQ total summary score served as the reference
measure in the calculation of RE ratios. Correlation
between measures was calculated using Pearson’s correla-
tion coefficients (r). Strength of correlation was categorized
as follows: absent (<0.20), poor (0.20-0.34), moderate
(0.35-0.50) and strong (>0.50) [27]. A p-value < 0.05 was
interpreted as statistically significant.
We hypothesized that the correlations between SGRQ
and clinical measures, i.e. Borg dyspnea scale and
6MWT, would be stronger than between the summary
scores of generic measures and the clinical measures, as
SGRQ includes items specifically related to breathing
problems. We also hypothesized moderate to strong
correlations between the summary scores of the SGRQ,
SF-36, and EQ-5D.
Results
The mean (SD) age of the cohort was 71.3 (±10.3), and
greater than 90% were white males. Patient characteristics
did not differ across stages of COPD severity (Table 1).
The exception was number of years smoked, which was
significantly lower among patients with mildest stage of
COPD (p = 0.02).
Mean FEV1, 6MWT, and Borg dyspnea scores were
significantly different across GOLD stage (ANOVA/
KWT, p-values < 0.001), with poorer functioning
observed for patients with more severe COPD (Table 2).
Mean symptom, activity, and impact and total SGRQ
scores were significantly different across stages of
disease, (ANOVA/KWT, all p-values < 0.001 except a
p-value of 0.03 for symptom score), with activity and
total scores getting worse with stage of disease. Mean
SGRQ symptom and impact scores declined across
stages 1 to 3, but stage 4 scores were slightly less severe
than stage 3. Mean PCS and MCS scores both demon-
strated a trend towards decline in health status with
COPD severity, but only PCS mean scores were statisti-
cally different across COPD stage (p = 0.02). The mean
EQ-5D index score (both UK and US) did not differ
across the stages (p = 0.25). Mean EQ-5D VAS scores
were different across stage of disease, with lower mean
scores for more severe stage of disease (p = 0.02).
Using the SGRQ total score as the reference, relative
efficiency ratios indicated that summary scores for SF-
36 and EQ-5D were less efficient at discriminating
between COPD stages (RE < 1) (Table 2). For the pur-
pose of discriminating among COPD patients according
to stage of disease, results indicated that only the SGRQ
activity component score was more efficient than the
SGRQ total score, i.e. RE > 1 (Table 2).
SGRQ activity and total scores demonstrated stron-
ger correlations with the clinical measures than the
other HRQL scores, although all HRQL measures had
moderate to strong correlations with the dyspnea scale
(Table 3). The summary scores of the generic mea-
sures - SF-36 PCS and MCS and EQ-5D index and
VAS - were poorly correlated with FEV1 (r < 0.2), and
poor-to-moderately correlated with 6MWT (r = 0.16
to 0.40). SGRQ total and impact scores were strongly
correlated with both SF-36 and EQ-5D scores (r ≥ 0.5).
The SGRQ symptom score exhibited moderate correla-
tion with SF-36 and EQ-5D summary scores (0.35 ≤
r < 0.5). The correlation between the activity score and
the generic instruments ranged from poor-to-moderate
(0.2 ≤ r < 0.5).
Table 1 Patient Characteristics
Characteristic
Mean (SD)
Total Sample
(n = 120)
GOLD
Stage 1
(n = 23)
GOLD
Stage 2
(n = 53)
GOLD
Stage 3
(n = 27)
GOLD
Stage 4
(n = 17)
p-value
Age 71.2 (10.3) 72.3 (11.5) 71.7 (11.4) 70.4 (8.4) 73.3 (7.9) 0.82
‡
Male, n (%) 118 (98.3) 23 (100) 52 (98.1) 26 (96.3) 17 (100) 0.71
†
Race, n (%) 0.18
†
White 113 (94.2) 20 (87.0) 52 (98.1) 26 (96.3) 15 (88.2)
Black 6 (5.0) 3 (13.0) 0 (0.0) 1 (3.7) 2 (11.8)
Other 1 (0.8) 0 (0.0) 1 (1.9) 0 (0.0) 0 (0.0)
Smoking status, n (%) 0.18
†
Current 11 (9.2) 3 (13.0) 8 (15.1) 8 (29.6) 0 (0.0)
Past 90 (75.0) 17 (73.9) 39 (73.6) 18 (66.7) 16 (94.1)
Never 19 (15.8) 3 (13.0) 6 (11.3) 1 (3.7) 1 (5.9)
BMI (Kg/m
2) 29.1 (5.2) 30.6 (4.3) 29.6 (5.1) 29.2 (5.6) 25.3 (4.6) 0.01
‡
Smoke-years (n = 109) 33.7 (15.0) 26.2 (13.0) 34.6 (15.2) 39.5 (13.3) 31.3 (16.1) 0.02
‡
Packs/day (n = 105) 1.57 (0.83) 1.71 (1.10) 1.51 (0.88) 1.44 (0.60) 1.75 (0.68) 0.56
‡
Pack-years (n = 109) 54.0 (37.9) 48.9 (46.0) 54.3 (42.2) 55.2 (26.2) 57.0 (32.7) 0.93
‡
†based on Chi-square or
‡ANOVA.
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The results of this study supported the hypothesis that
the disease-specific SGRQ had greater ability to discri-
minate among levels of COPD severity than generic
measures of HRQL, i.e. SF-36 and EQ-5D. This finding
is consistent with the other results that indicate the
SGRQ is more strongly correlated with clinical measures
than the summary scores of the generic measures. The
correlation between generic HRQL summary scores -
SF-36 and EQ-5D - and FEV1 was trivial, similar to a
previous study [6]. GOLD stage is predicated upon
breathing function, and the generic measures do not
directly include items on breathing-related symptoms,
while SGRQ does include such items. The RE ratios
favoured the SGRQ total and activity scores, which sug-
gests that those scales may provide greater statistical
power to detect significant differences/changes in HRQL
in COPD patients than the other measures, particularly
if the study is intended to capture changes related to
clinical severity.
Greater discriminative ability of disease-specific mea-
sures compared to generic HRQL measures has been
reported in studies of other conditions [28-30]. In per-
ipheral arterial disease, the disease-specific Vascular
Q u a l i t yo fL i f e( V a s c u Q o l )m e a s u r ew a sm o r ed i s c r i m i -
native than the EQ-5D and SF-36 [28]. In rheumatoid
arthritis, Marra et al. found that the Rheumatoid Arthri-
tis Quality of Life Questionnaire had greater ability to
Table 2 Patient Clinical and Quality-of-Life Measurements (Total N = 120)
Measure
mean (SD)
Total Sample
(n = 120)
GOLD
Stage 1
(n = 23)
GOLD
Stage 2
(n = 53)
GOLD
Stage 3
(n = 27)
GOLD
Stage 4
(n = 17)
ANOVA ANOVA KWT
F-stat RE p-value p-value
FEV1 (%) 58.4 (24.8) 92.9 (13.7) 65.5 (9.1) 37.4 (5.7) 23.0 (4.8) 254.2 <0.001 <0.001
6MWT (m) 312.5 (108.0) 356.7 (124.3) 321.0 (95.8) 315.0 (98.8) 222.5 (89.6) 6.01 <0.001 <0.001
Borg Dyspnea 2.48 (1.64) 1.19 (1.11) 2.33 (1.65) 3.48 (1.67) 3.12 (0.49) 11.55 <0.001 <0.001
SGRQ Total 41.3 (19.7) 28.8 (15.0) 37.2 (18.6) 52.2 (19.6) 54.1 (13.5) 11.15 Ref <0.001 <0.001
SGRQ Symptom 50.0 (24.1) 42.4 (21.4) 46.8 (23.9) 60.1 (26.1) 54.4 (20.2) 2.98 0.27 0.03 0.02
SGRQ Activity 57.3 (27.6) 38.0 (23.8) 53.5 (28.1) 65.7 (23.0) 82.5 (10.0) 12.36 1.11 <0.001 <0.001
SGRQ Impact 29.9 (18.9) 19.4 (14.9) 25.8 (16.3) 41.9 (20.0) 37.8 (17.5) 9.34 0.84 <0.001 <0.001
SF-36 PCS 34.4 (9.6) 39.5 (10.1) 34.4 (10.7) 32.4 (7.8) 30.9 (4.2) 3.49 0.31 0.02 0.002
SF-36 MCS 49.6 (10.9) 52.60 (9.4) 50.5 (10.4) 47.9 (12.5) 45.5 (10.7) 1.75 0.16 0.16 0.114
EQ-5D US Index 0.73 (0.19) 0.80 (0.13) 0.70 (0.21) 0.72 (0.19) 0.72 (0.16) 1.35 0.11 0.26 0.079
EQ-5D UK Index 0.63 (0.27) 0.73 (0.19) 0.59 (0.32) 0.63 (0.25) 0.63 (0.24) 1.38 0.12 0.25 0.069
EQ-5D VAS 65.3 (18.9) 74.3 (16.3) 66.2 (20.0) 60.1 (18.4) 58.7 (15.8) 3.31 0.30 0.02 0.004
GOLD: global burden of obstructive lung disease; Ref: Reference; RE: Relative efficiency ratio; SGRQ: St. George’s Respiratory Questionnaire; ref: reference; ANOVA:
analysis of variance; KWT: Kruskal-Wallis test.
Table 3 Correlations between Clinical and HRQL Measures
FEV1 6MWT Borg
Dyspnea
SF-36
PCS
SF-36
MCS
EQ-5D index
(UK)
EQ-5D index
(US)
EQ-5D
VAS
SGRQ
Total
SGRQ
Symptom
SGRQ
Activity
FEV1 1
6MWT 0.28
† 1
Borg
Dyspnea
-0.41
§ -0.21
† 1
SF-36 PCS 0.19
† 0.40
§ -0.58
§ 1
SF-36 MCS 0.14 0.16 -0.34
§ 0.15 1
EQ-5D Index
(UK)
0.01 0.21
† -0.48
§ 0.51
§ 0.54
§ 1
EQ-5D Index
(US)
0.03 0.21
† -0.48
§ 0.51
§ 0.56
§ 0.99
§ 1
EQ-5D VAS 0.16 0.31
§ -0.48
§ 0.69
§ 0.49
§ 0.52
§ 0.53
§ 1
SGRQ Total -0.43
§ -0.30
§ 0.76
§ -0.67
§ -0.50
§ -0.55
§ -0.57
§ -0.60
§ 1
SGRQ
Symptom
-0.24
† -0.03 0.51
§ -0.42
§ -0.35
§ -0.36
§ -0.38
§ -0.36
§ 0.73
§ 1
SGRQ Activity -0.45
§ -0.46
§ 0.70
§ -0.67
§ -0.40
§ -0.47
§ -0.48
§ -0.53
§ 0.88
§ 0.48
§ 1
SGRQ Impact -0.36
§ -0.21
† 0.72
§ -0.59
§ -0.50
§ -0.56
§ -0.58
§ -0.60
§ 0.94
§ 0.63
§ 0.72
§
† p < 0.05,
§ p < 0.001.
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than the EQ-5D and SF-6D [30].
The EQ-5D VAS was better able to discriminate levels
of HRQL according severity of disease than the EQ-5D
index score in COPD patients. Unlike EQ-5D index-based
scores, mean EQ-5D VAS scores decreased monotonically
with stage of COPD, and the difference in VAS mean
scores by severity represented what could be considered
an important difference in VAS scores between stage 1, 2
a n d3[ 3 1 ] .I ti si m p o r t a n tt on o t et h a tC O P Di so f t e n
accompanied by other co-morbid conditions which were
not captured in our data and may differentially affect the
ability of HRQL measures to capture burden of illness.
Our study contributes to the literature on HRQL mea-
surement in COPD in several ways. We present further
evidence to support the validity of disease-specific and
generic measures consistent with a previous study [5],
but in a cohort of older and more severe COPD
patients. Similar to Stahl and colleagues, we found that
SGRQ total, PCS, and EQ-5D index and VAS scores got
worse with severity based on GOLD stage [5]. Particular
to this study, we showed that SGRQ scores were asso-
ciated with greater statistical power to discriminate
among levels of COPD severity using REs. We also
found that the strengths of correlation between mea-
sures and EQ-5D index-based scores were nearly identi-
cal regardless of whether the UK or US value set was
employed, because the correlation was nearly perfect
(r = 0.993) between the EQ-5D index-based scores gen-
erated by each value set. For users of these measures,
this study shows that the SGRQ has the advantage over
generic measures in that it may be more likely to obtain
a statistically significant result on a HRQL score if there
are clinically meaningful differences/changes among
patients. In addition, the EQ-5D index-based scores did
not differentiate between the more severe stages of
COPD. However, it is unclear if unobserved factors like
comorbid conditions that might have been captured by
the generic measure had a role in this finding.
This study had some limitations. The sample size used
in our analyses may have yielded insufficient power to
detect important differences across the severity stages.
However, it was sufficiently powered to detect significant
differences in EQ-5D scores [31]. Our data was cross-
sectional; therefore, we could not compare the responsive-
ness of the measures over time. Use of a clinically-based
measure of severity (GOLD stage) as the basis for compar-
ing HRQL instruments may be suboptimal, but there is no
clear gold standard for anchoring known-group compari-
sons of HRQL measures. Since the data used in our study
were collected, modified versions of the SGRQ and
EQ-5D have been introduced. These are all considerations
for future studies comparing the psychometric perfor-
mance of HRQL measures in studies of COPD patients.
Conclusions
The SGRQ demonstrated greater ability to discriminate
among different levels of severity stages of COPD and is
more strongly correlated with clinical measures of
COPD than generic measures of health. However, gen-
eric measures are intended to capture more broad
aspects of health, and thus scores may potentially be
less strongly correlated with clinical measures because
they are capturing additional information on HRQL that
is non-COPD related. For these reasons, generic and
disease-specific measures may capture complementary
information and it may be desirable to incorporate both
types of measures in a study, depending on the goal of
the study. As new versions of these widely used HRQL
measures become available, such as a 5-level version of
the EQ-5D, further comparisons - particularly using
longitudinal data - will be useful in understanding the
psychometric strengths and weaknesses of generic and
disease-specific HRQL measures for the assessment and
monitoring of COPD patient outcomes.
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